Multicenter randomized Phase III Trial of concurrent chemoradiotherapy(CCRT) with Cisplatin versus CCRT with Cisplatin and Paclitaxel for locally uterine cervix adenocarcinoma
| Project/Area Number |
25462598
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | University of the Ryukyus |
|---|
Principal Investigator |
Nagai Yutaka 琉球大学, 医学(系)研究科(研究院), 准教授 (70305209)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
戸板 孝文 琉球大学, 医学(系)研究科(研究院), 客員教授 (30237036)
稲嶺 盛彦 琉球大学, 医学(系)研究科(研究院), 講師 (90437989)
久高 亘 琉球大学, 医学部附属病院, 講師 (50529336)
大山 拓真 琉球大学, 医学(系)研究科(研究院), 助教 (40713350)
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 子宮頸部腺癌 / 同時化学放射線療法 / 多施設共同研究 / 第Ⅲ相試験 / シスプラチン / パクリタキセル / 観察研究 / 第III相試験 |
|---|
| Outline of Final Research Achievements |
Concurrent chemoradiotherapy (CCRT) using cisplatin is gold-standard treatment for advanced carcinoma of the uterine cervix. Although it is unclear whether cisplatin-based concurrent chemoradiotherapy has the same effect on adenocarcinoma as on squamous cell carcinoma.To evaluate safety and efficacy of CCRT with cisplatin (CCRT-P) vs CCRT with cisplatin and paclitaxel (CCRT-TP) for locally uterine cervix adenocarcinoma, we conducted a pahse III study for CCRT-P vs CCRT-TP. Because of poor enrollment for this study, we had to decide early termination of this trial. Immediately after this, We planned a national survey by patient who received CCRT for locally uterine cervix adenocarcinoma at this time. The altenative study showed that CCRT-TP achieved much better overall survival for adenocarcinoma of the uterine cervix.
|
Report
(4 results)
Research Products
(6 results)
